Hope Rugo<\/strong> (City of Hope Comprehensive Cancer Center, USA) addressed the sequencing of ADCs in HR-positive\/HER2-negative disease, covering data on sacituzumab govitecan after endocrine therapy and CDK4\/6 inhibitor failure, datopotamab deruxtecan in TROPION-Breast01, and trastuzumab deruxtecan in HER2-low and HER2-ultralow HR-positive disease based on DESTINY-Breast06. The presentation also addressed where these ADCs may fit within the treatment sequence.<\/p>\n The first session concluded with a panel discussion and audience Q&A. The speakers were joined by Caroline Preu\u00df<\/strong> (Kepler University Hospital Linz, Austria), Annette Reiner<\/strong> (Medical University of Innsbruck, Austria), and Gabriel Rinnerthaler<\/strong> (ABCSG Vice President, Medical University of Graz, Austria).<\/p>\n Part 2 focused on treatment strategies in HER2-positive and triple-negative metastatic breast cancer.<\/p>\n Rupert Bartsch<\/strong> (Medical University of Vienna, Austria) explored maintenance strategies in HER2-positive disease and the potential of bringing treatments into earlier lines, with a particular focus on the role of tucatinib in earlier treatment settings and data from the PATINA and HER2CLIMB-05 studies.<\/p>\n Marija Balic<\/strong> (University of Pittsburgh School of Medicine, USA) examined the potential of moving ADCs into the first-line treatment of metastatic triple-negative breast cancer, with a focus on data from ASCENT-04, ASCENT-03, and TROPION-Breast02. The presentation addressed the potential of ADCs to replace chemotherapy in the first-line setting and the question of which ADC should be used for patients with metastatic TNBC.<\/p>\n A second panel discussion and audience Q&A brought together the speakers and the discussants to consider the clinical implications of these evolving treatment strategies.<\/p>\n The webinar concluded with a wrap-up and closing by Michael Gnant.<\/p>\n The educational event was approved for 3 continuing medical education credits from the Austrian Medical Chamber (\u201cDFP-Punkte\u201d).<\/p>\n
![\"Gilead\"](\"https:\/\/www.abcsg.org\/wp\/wp-content\/uploads\/2024\/02\/Gilead_Logo.jpg\"){kind=logo}
<\/figure>\n<\/div>\n\n\n\n![\"Pfizer\"](\"https:\/\/www.abcsg.org\/wp\/wp-content\/uploads\/2023\/03\/Pfizer_Logo_Color_RGB-3.png\"){kind=logo}
<\/figure>\n<\/div><\/div>\n\n\n\n